Skip to main content

ORIGINAL RESEARCH article

Front. Microbiol.

Sec. Antimicrobials, Resistance and Chemotherapy

Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1531984

This article is part of the Research Topic Outbreak Investigations of Nosocomial Infections View all 12 articles

Seven-year change of prevalence, clinical risk factors, and mortality of patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a Chinese teaching hospital: a case-case-control study

Provisionally accepted
Haifang Kong Haifang Kong 1Yong Liu Yong Liu 2Ling Yang Ling Yang 1Qianqian Chen Qianqian Chen 1Yanchun Li Yanchun Li 1Zhidong Hu Zhidong Hu 1Xuequan Feng Xuequan Feng 2*Yamin Chai Yamin Chai 1*Zuoliang Dong Zuoliang Dong 1*
  • 1 Tianjin Medical University General Hospital, Tianjin, China
  • 2 Tianjin First Central Hospital, Tianjin, China

The final, formatted version of the article will be published soon.

    Carbapenem-resistant Klebsiella pneumoniae bloodstream infection (CRKP-BSI) is a major public health threat worldwide. CRKP-BSI is associated with poor outcomes, elevated morbidity and mortality, and high healthcare costs. Therefore, the identification of risk factors for CRKP-BSI and mortality are critical for preventing and controlling CRKP in hospitals. This retrospective case-casecontrol study was conducted at General Hospital of Tianjin Medical University, a tertiary teaching hospital, from 2017 to 2023. It included 105 patients with CRKP-BSI (case group 1) and matched 105 patients with carbapenem-susceptible K. pneumoniae bloodstream infection (CSKP-BSI) (case group 2). The control group was selected at a ratio of 1:1:1 (case group1: case group 2: control) from patients with a positive blood culture (except for K. pneumoniae infection) to analyze risk factors associated with the two case groups and compare the 30-day survival curves using multivariable logistic regression and Kaplan-Meier analyses. Multivariate analysis revealed that liver disease was a risk factor for K. pneumoniae-BSI, and exposure to carbapenem (odds ratio [OR] = 3.24), tigecycline (OR = 3.43), and glucocorticoids (OR = 4.64) were independent risk factors for CRKP-BSI. The 30day mortality of the CRKP-BSI group was 30.5%, and patient groups, respiratory diseases (HR = 3.52), use of 3rd-generation cephalosporins (HR = 1.92), mechanical ventilation (HR = 2.14), and central venous catheter insertion (HR = 2.85) were independent risk factors, whereas a shorter length of hospitalization was a protective factor for 30-day mortality. The in-hospital mortality in the CRKP-BSI group was 55.2%, and arterial catheter use (OR = 3.76) was an independent risk factor for in-hospital mortality. Several factors were identified to contribute to the development of CRKP-BSI. CRKP isolates were resistant to most antibiotics. Reducing CRKP-BSI-related mortality requires comprehensive consideration of underlying diseases, judicious antibiotic use, and invasive procedures. The high morbidity, mortality, along with the limited therapeutic options for CRKP-BSI, underscore the need for improved detection, identification of risk factors to develop effective preventive measures, and development of novel agents with reliable clinical efficacy against CRKP.

    Keywords: Risk factors, Carbapenem resistance, Klebsiella pneumoniae, Bloodstream infection, case-case-control study

    Received: 21 Nov 2024; Accepted: 07 Mar 2025.

    Copyright: © 2025 Kong, Liu, Yang, Chen, Li, Hu, Feng, Chai and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xuequan Feng, Tianjin First Central Hospital, Tianjin, China
    Yamin Chai, Tianjin Medical University General Hospital, Tianjin, China
    Zuoliang Dong, Tianjin Medical University General Hospital, Tianjin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more